Mitodicure receives support from the German Federal State of Hesse and the European Union

Important Milestone Reached for Conducting Preclinical Studies.

Mitodicure GmbH is entitled to a grant to select a preclinical drug candidate for the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). This grant is co-funded by the German Federal State of Hesse and the European Union within the funding line ‘R&D projects in companies’ (Leitstrukturauswahl zur Behandlung von ME/CFS im Rahmen der Förderlinie F&E-Vorhaben in Unternehmen).

ME/CFS is a disease with no treatment option. Exercise intolerance and post-exertional malaise are the main symptoms. These are due to an energy deficit caused by mitochondrial dysfunction of the skeletal muscle and are to be treated with a small molecule therapeutic in tablet form.